Drug Trial Radar · NCT00500656
Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)
Last checked: Nov 20, 2026Latest source record: Jun 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
85
Actual
Start
Mar 1, 2005
Primary completion
Jul 25, 2006
Study completion Jul 25, 2006
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Jul 13, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Outcome Measures: The primary endpoint was the time to onset of symptom relief of the first attack in the double blind phase. H0: λ icatibant/λ tranexamic acid =1 versus H1: λ icatibant/λ tranexamic acid ≠1 Where: λ icatibant refers to the hazard rate under icatibant and λ tranexamic acid refers to the hazard rate under tranexamic acid. Secondary Outcome Measures: * Additional efficacy assessments (Time to Almost Complete Symptom Relief) * Safety and tolerability * Pharmacoeconomics
Conditions
- Hereditary Angioedema
Interventions
IcatibantDrug
Icatibant: a stable, synthetic decapeptide and specific BK B2 receptor antagonist.
Tranexamic AcidDrug
over encapsulated film tablet an anti-fibrinolytic agent,is used in some European countries for the treatment of acute oedema episodes and the continuous prophylaxis of HAE.
Oral PlaceboDrug
hard capsule matched to tranexamic acid
S.C. PlaceboDrug
solution for injection, matched to icatibant for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Onset of Symptom Relief.Time frame: 2 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Università degli Studi di Milano, Dipartimento di Medicina Interna
Milan, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.